Answers are grounded in this paper and cite their sources.
Case report shows complete remission with pembrolizumab in a patient with xeroderma pigmentosum and metastatic melanoma, indicating immune checkpoint inhibitors may be effective.
Xeroderma pigmentosum (XP) is a rare genetic disorder associated with defective DNA repair, leading to extreme ultraviolet sensitivity and a significantly elevated risk of malignancies. This case report details a patient with XP and metastatic melanoma who achieved complete clinical remission with pembrolizumab, highlighting the potential efficacy of immune checkpoint inhibitors in tumours with high mutational burdens. These findings underscore a promising therapeutic avenue for this vulnerable population with limited treatment options.
No takes yet. Share an insight, caveat, or question.
Martins et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: